NDC codes

FDA NDC Directory
Product NDC (as listed)71288-818Labeler and product segments. Claims need a package NDC.
Product NDC at billing width71288-0818Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
71288-818-8171288081881712880818812 SYRINGE, GLASS in 1 CARTON (71288-818-81) / .8 mL in 1 SYRINGE, GLASSMarketed from Sep 25, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Yusimry
Generic name (nonproprietary)
adalimumab-aqvh
Active ingredients
Adalimumab — 80 mg/.8mL
Dosage form
Injection, Solution
Route
Subcutaneous
Labeler
Meitheal Pharmaceuticals Inc.NDC labeler code 71288
Product type
Prescription drug
Marketing category
BLA — Biologics License ApplicationApplication BLA 761216
Marketing start
Listing expires
Other FDA classes
Monoclonal (Chemical structure)Tumor Necrosis Factor Receptor Blocking Activity (Mechanism)
Identifiers
Product ID 71288-818_5ba63c53-78a7-413a-8b38-2e614af61f69SPL ID 5ba63c53-78a7-413a-8b38-2e614af61f69

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0135 — Injection, adalimumab, 20 mg

Billing unit: 20 mg. Units on the claim = dose given ÷ 20 mg.

Adalimumab is usually self-administered and dispensed through a pharmacy benefit. Adalimumab biosimilars are listed under their own names.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471288081881 followed by a unit qualifier and the quantity

Package 71288-0818-81. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 71288-818

What is NDC 71288-818?
71288-818 is the product NDC for Yusimry (adalimumab-aqvh), Adalimumab 80 mg/.8mL injection, solution, listed with the FDA by Meitheal Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Yusimry (Adalimumab-aqvh).
What is the active ingredient?
Adalimumab.
Who is the labeler?
Meitheal Pharmaceuticals Inc., NDC labeler code 71288. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Yusimry?
5 other product NDCs are listed under this name. See all Yusimry NDCs.
Is there a related HCPCS / J-code?
Yes: J0135, Injection, adalimumab, 20 mg. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Yusimry NDCs
ProductStrengthForm · routeLabelerProduct NDCPackage NDCs (11-digit)
Yusimryadalimumab-aqvhAdalimumab 40 mg/.4mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-81771288-0817-81
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousCoherus BioSciences Inc70114-21070114-0210-02
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousCoherus BioSciences Inc70114-22070114-0220-02
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-81571288-0815-81
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-81671288-0816-81

Other NDCs under BLA 761216

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761216
ProductStrengthForm · routeLabelerProduct NDC
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousCoherus BioSciences Inc70114-210
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousCoherus BioSciences Inc70114-220
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-815
Yusimryadalimumab-aqvhAdalimumab 40 mg/.8mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-816
Yusimryadalimumab-aqvhAdalimumab 40 mg/.4mLInjection, SolutionSubcutaneousMeitheal Pharmaceuticals Inc.71288-817

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in